Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks

Magdalena Śmiech, Paweł Leszczyński, Hidetoshi Kono, Christopher Wardell and Hiroaki Taniguchi

1 Institute of Genetics and Animal Biotechnology, Laboratory for Genome Editing and Transcriptional Regulation, Polish Academy of Sciences, 05-552 Jastrzębiec, Poland; m.smiech@igbzpan.pl (M.Ś.); p.leszcynski@igbzpan.pl (P.L.)
2 Molecular Modeling and Simulation Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Kizugawa, Kyoto 619-0215, Japan; kono.hidetoshi@qst.go.jp
3 Department of Biomedical Informatics, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA; CPWardell@uams.edu

* Correspondence: h.taniguchi@igbzpan.pl; Tel.: +48-22-736-70-95

Received: 4 October 2020; Accepted: 3 November 2020; Published: 12 November 2020

Abstract: Gene mutations can induce cellular alteration and malignant transformation. Development of many types of cancer is associated with mutations in the B-raf proto-oncogene (BRAF) gene. The encoded protein is a component of the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) signaling pathway, transmitting information from the outside to the cell nucleus. The main function of the MAPK/ERK pathway is to regulate cell growth, migration, and proliferation. The most common mutations in the BRAF gene encode the V600E mutant (class I), which causes continuous activation and signal transduction, regardless of external stimulus. Consequently, cell proliferation and invasion are enhanced in cancer patients with such mutations. The V600E mutation has been linked to melanoma, colorectal cancer, multiple myeloma, and other types of cancers. Importantly, emerging evidence has recently indicated that new types of mutations (classes II and III) also play a paramount role in the development of cancer. In this minireview, we discuss the influence of various BRAF mutations in cancer, including aberrant transcriptional gene regulation in the affected tissues.

Keywords: BRAF; MAPK/ERK; oncogene; mutations; transcription factors; cancer

1. Introduction

In the human genome, the B-raf proto-oncogene (BRAF) gene is located on chromosome 7 (7q34) and encodes the BRAF protein, which is composed of 766 amino acids. While all RAF proteins can phosphorylate MEK (MEK1 and MEK2), BRAF has the strongest activation capacity. Accordingly, the mitogen activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) signaling pathway (also known as the Ras-Raf-MEK-ERK pathway) is stimulated and thus regulates cell proliferation, differentiation, and apoptosis, in response to extracellular stimuli, such as cytokines, growth factors, hormones, and environmental stressors. Activation of Raf-MEK-ERK pathway is also known to stimulate the expression of many target genes [1–3]. ERK (ERK1 and ERK2) is activated by MEK in the cytoplasm and transported in the nucleus of cells. In the nucleus, ERK1/2 activates through phosphorylation of many transcription factors [4–6]. Dysregulation in the MAPK/ERK cascade due to mutations in constituent proteins of this pathway, including RAS (KRAS and NRAS) and RAF (BRAF), is associated with many types of cancer [7,8].
BRAF has three highly conserved domains (CR1, CR2, and CR3). CR1 and CR2 are regulatory regions located toward the N-terminal of the protein. CR1 encompasses the RAS-binding domain (RBD), which interacts with RAS and the cysteine-rich domain (CRD) that binds two zinc ions. CR2 is a serine/threonine rich domain with a 14-3-3 binding site. CR3 has a kinase domain that is located on the C-terminal and is regulated through phosphorylation (Figure 1A) [9–11]. The BRAF kinase domain is distinguished by two sections: a small N-terminal lobe and a large C-terminal lobe. The small lobe contains a glycine-rich ATP-phosphate-binding loop, which is also known as the P-loop. In the inactive BRAF kinase state, a crystal structure [12] shows that the P-loop and the activation segment with Asp-Phe-Gly (DFG) motif are positioned near each other and likely stabilized due to an array of hydrophobic interactions, while in another structure [13] the activation segment forms α-helices before the DFG motif (Figure 1B). Phosphorylation of the activating loop leads to BRAF activation. As a result, the hydrophobic interactions or the α-helices are destabilized and the conformational change are induced. This eventually makes the catalytic cleft available. Among all the proteins of RAF family members, BRAF is the main activator of MEK kinases. This is due to BRAF’s constant phosphorylation at residue S446 and negatively charged aspartic acid residues at position D448 and D449. These later residues are in the N-region, which results in a negative charge and facilitates its activation through RAS [7,14]. In contrast to BRAF, CRAF and ARAF require enzyme-catalyzed residue phosphorylation for activation [15]. The BRAF kinase activation segment is evolutionarily conserved among many species. More importantly, mutations of BRAF are found in many forms of cancers and the mutations are classified into three subtypes according to their activation pathways (Figure 2). Although the mechanism of how the mutations induce malignancy is different in terms of their interaction with RAS pathway and partners to form dimers, they all are known to activate ERK phosphorylation. In this review, we will discuss potential transcriptional networks that can mediate BRAF mutation signal to cause malignancy and disrupted gene regulations in the presence of BRAF mutation in several cancers (Tables 1 and 2).

Figure 1. B-raf proto-oncogene (BRAF) protein structure. (A) Positions of typical three classes of BRAF mutations are presented. BRAF mutations are indicated in the human BRAF protein structure (CR1; blue, CR2; red, CR3; green). (B) Active (cyan, Protein Data Bank (PDB) code 4MNF [16]) and inactive (gray and orange, PDB code 3TV6 [13,16,17]) forms of BRAF. In the active form, E600 (mutation of V600) and K507 form a salt-bridge that drastically changes the position of the αC helix and destabilizes the activation segment (AS, shown in orange). Asp-Phe-Gly (DFG) motif is shown in red.
Figure 2. The classification of BRAF mutations and their signaling pathways. Class I is related to codon 600. BRAF V600 (BRAF Mut) acts as a monomer in an RAS-independent manner (RAS WT) and constitutively activate extracellular signal-regulated kinases (ERK) by phosphorylation. In class II signal transduction involves non-V600 mutant. Strong kinase activation is regulated by dimers of mutant BRAF (BRAF Mut), independently of RAS (RAS WT). Class III is kinase-impaired and consists of BRAF non-600 mutant (BRAF Mut) and CRAF wild type (CRAF WT) as a heterodimer. The signal is transferred downstream in the presents of RAS mutant (RAS Mut).

Table 1. BRAF D594 mutation in different type of cancers found in literature.

| Mutation ID | Genomic DNA Change | Location of Mutations | Diagnosis                                      | Clinical Significance | References |
|-------------|--------------------|----------------------|------------------------------------------------|-----------------------|------------|
|             | chr7: g.140453136   | V600E                | Metastatic colorectal cancer                   |                       | [18]       |
|             | A > T               |                      | Melanoma                                       |                       | [19]       |
|             |                     |                      | Multiple myeloma                               |                       | [20]       |
|             |                     |                      | Metastatic colorectal cancer                   |                       | [18]       |
|             |                     |                      | Non-small cell lung cancers                    |                       | [8]        |
|             |                     |                      | Multiple myeloma                               |                       | [20]       |
|             |                     |                      | Non-small cell lung cancers                    |                       | [8]        |
|             |                     |                      | Multiple myeloma                               |                       | [20,21]    |

Table 2. Three classes of BRAF mutations identified by the International Cancer Genome Consortium (ICGC) and their clinical significance in different types of cancer.

| Mutation ID | Genomic DNA Change | Location of Mutations | Clinical Significance | Donors Affected | Cancer Type                                      |
|-------------|--------------------|----------------------|-----------------------|-----------------|------------------------------------------------|
|             | chr7: g.140453136  | V600E                | Pathogenic            | 814             | Bladder Urothelial Cancer                        |
|             | A > T               |                      |                       |                 | Chronic Lymphocytic Leukemia                     |
|             |                     |                      |                       |                 | Colorectal Cancer                                |
|             |                     |                      |                       |                 | Colorectal Cancer                                |
|             |                     |                      |                       |                 | Brain Glioblastoma Multiforme                    |
|             |                     |                      |                       |                 | Head and Neck Squamous Cell Carcinoma            |
|             |                     |                      |                       |                 | Kidney Renal Papillary Cell Carcinoma            |
|             |                     |                      |                       |                 | Brain Lower Grade Glioma                         |
|             |                     |                      |                       |                 | Liver Cancer                                     |
|             |                     |                      |                       |                 | Lung Adenocarcinoma                              |
|             |                     |                      |                       |                 | Malignant Lymphoma                               |
|             |                     |                      |                       |                 | Skin Cancer                                      |
|             |                     |                      |                       |                 | Pediatric Brain Cancer                           |
|             |                     |                      |                       |                 | Rectum Adenocarcinoma                            |
|             |                     |                      |                       |                 | Skin Adenocarcinoma                              |
|             |                     |                      |                       |                 | Skin Cutaneous Melanoma                          |
|             |                     |                      |                       |                 | Thyroid Cancer                                   |
|             |                     |                      |                       |                 | Head and Neck Thyroid Carcinoma                  |
| Mutation ID | Genomic DNA Change | Location of Mutations | Clinical Significance | Donors Affected | Cancer Type |
|------------|--------------------|-----------------------|-----------------------|-----------------|-------------|
| MU32987175 | chr7: g.140453137 C>T | V600M | Likely pathogenic | 54 | Skin Cancer Skin Adenocarcinoma Skin Cutaneous Melanoma |
| MU40909253 | chr7: g.140453136 AC>TT | V600K | Pathogenic | 17 | Skin Cancer |
| MU44780501 | chr7: g.140453136 AC>CT | V600R | Pathogenic | 2 | Skin Cancer |
| MU44927644 | chr7: g.140453136CA>GT | V600D | - | 1 | Skin Cancer |

**CLASS II**

| Mutation ID | Genomic DNA Change | Location of Mutations | Clinical Significance | Donors Affected | Cancer Type |
|------------|--------------------|-----------------------|-----------------------|-----------------|-------------|
| MU1846952  | chr7: g.140453134 T>C | K601E | Pathogenic | 16 | Chronic Lymphocytic Leukemia Lymphoid Neoplasm Diffuse Large B-Cell Lymphoma Skin Cancer Prostate Adenocarcinoma Skin Cutaneous Melanoma Gastric Adenocarcinoma Head and Neck Thyroid Carcinoma Uterine Corpus Endometrial Carcinoma |
| MU161538   | chr7: g.140449142 C>G | G469A | Pathogenic | 14 | Bladder Cancer Bladder Urothelial Cancer Chronic Lymphocytic Leukemia Colon Adenocarcinoma Early Onset Prostate Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma Oral Cancer Prostate Adenocarcinoma Skin Cutaneous Melanoma Gastric Adenocarcinoma Skin Adenocarcinoma |
| MU36259478 | chr7: g.140449142 C>A | G469V | Pathogenic | 6 | Lung Adenocarcinoma Malignant Lymphoma |
| MU1299736  | chr7: g.140449143 C>T | G469R | Likely pathogenic | 6 | Lung Squamous Cell Carcinoma Skin Cancer Skin Cutaneous Melanoma |
| MU1334968  | chr7: g.140449147 C>A | G464V | Pathogenic/Likely pathogenic | 3 | Biliary Tract Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma |
| MU4410750  | chr7: g.140453145 A>T | L597Q | Pathogenic/Likely pathogenic | 2 | Chronic Lymphocytic Leukemia Skin Cutaneous Melanoma |
| MU50026    | chr7: g.140453132 T>A | K601N | Likely pathogenic | 2 | Chronic Lymphocytic Leukemia Blood Cancer - T-Cell and NK-Cell Lymphoma |
| MU44221302 | chr7: g.140453146 G>C | L597V | Pathogenic | 2 | Biliary Tract Cancer Colon Adenocarcinoma |
| MU12983017 | chr7: g.140449147 C>T | G464E | Pathogenic/Likely pathogenic | 1 | Uterine Corpus Endometrial Carcinoma |
| MU6236086  | chr7: g.140453133 T>G | K601T | Pathogenic/Likely pathogenic | 1 | Gastric Adenocarcinoma |

**CLASS III**

| Mutation ID | Genomic DNA Change | Location of Mutations | Clinical Significance | Donors Affected | Cancer Type |
|------------|--------------------|-----------------------|-----------------------|-----------------|-------------|
| MU126831   | chr7: g.140453135 C>T | D594N | Likely pathogenic | 13 | Colon Adenocarcinoma Colon Cancer Head and Neck Squamous Cell Carcinoma Liver Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma Malignant Lymphoma Skin Cutaneous Melanoma Gastric Adenocarcinoma |
| MU831694   | chr7: g.140453193 T>C | N581S | Likely pathogenic | 12 | Biliary Tract Cancer Chronic Lymphocytic Leukemia Kidney Renal Papillary Cell Carcinoma Liver Cancer Lung Adenocarcinoma Ovarian Serous Cystadenocarcinoma Skin Cutaneous Melanoma |
| Mutation ID  | Genomic DNA Change | Location of Mutations | Clinical Significance          | Donors Affected | Cancer Type                                                                 |
|-------------|--------------------|-----------------------|--------------------------------|----------------|-----------------------------------------------------------------------------|
| MU168532    | chr7: g.140481411 C > A | G466V                  | Pathogenic/Likely pathogenic  | 9              | Colon Adenocarcinoma Esophageal Adenocarcinoma Lung Adenocarcinoma Lung Squamous Cell Carcinoma Skin Cutaneous Melanoma |
| MU9763      | chr7: g.140453154 T > C | D594G                  | Pathogenic                    | 9              | Bladder Cancer Chronic Lymphocytic Leukemia Colorectal Cancer Brain Lower Grade Glioma Maligant Lymphoma Pancreatic Cancer Pancreatic Cancer Endocrine Neoplasms |
| MU4440100   | chr7: g.140481411 C > T | G466E                  | Likely pathogenic             | 8              | Breast Er+ and Her2- Cancer Head and Neck Squamous Cell Carcinoma Skin Cancer Skin Cutaneous Melanoma |
| MU4420958   | chr7: g.140481408 G > A | S467L                  | -                              | 5              | Skin Cancer Skin Cutaneous Melanoma                                         |
| MU1661062   | chr7: g.140481402 C > T | G469E                  | Pathogenic                    | 4              | Skin Cancer Oral Cancer Skin Cutaneous Melanoma                             |
| MU51987727  | chr7: g.140481411 C > G | G466A                  | Likely pathogenic             | 2              | Lung Adenocarcinoma Skin Cancer                                             |
| MU4622596   | chr7: g.140453149 C > G | G596R                  | Pathogenic/Likely pathogenic  | 2              | Bladder Cancer Lung Adenocarcinoma                                          |
| MU30632423  | chr7: g.140453154 T > G | D594A                  | Likely pathogenic             | 2              | Colorectal Cancer Liver Cancer                                               |
| MU63537540  | chr7: g.140453155 C > G | D594H                  | Pathogenic/Likely pathogenic  | 2              | Colorectal Cancer Lung Adenocarcinoma                                       |
| MU591874    | chr7: g.140453148 C > T | G964D                  | Likely pathogenic             | 1              | Brain Glioblastoma Multiforme                                               |
| MU4622598   | chr7: g.140453152 A > G | F995L                  | Pathogenic/Likely pathogenic  | 1              | Bladder Cancer                                                              |

2. Class I BRAF Mutations

There are three classes of BRAF mutations [22] as shown in Figure 2. Class I includes the BRAF V600E mutations and allows the BRAF to act as a constitutively active monomer. Class II mutations allow for constitutively active dimers. Class III either has impaired kinase activity or is inactive [23]. Tumor progression is associated with gene aberrations that modulate cell proliferation, differentiation, survival, and apoptosis. In particular, the accumulation of pathological changes in the proto-oncogenes leads to significant cellular defects [24]. Mutations in BRAF, NRAS, and KRAS components of the MAPK/ERK signaling pathway are frequently identified in melanoma, colorectal, multiple myeloma (MM), papillary thyroid, lung, and ovarian cancers [25–30]. BRAF is a major oncogenic driver and therefore a therapeutic target for drug development [31]. Nearly 7% of human cancers are associated with mutations in BRAF, and more than 90% of observed mutations of BRAF are the V600E mutation [32]. Replacement of valine (V) by glutamic acid (E) at position 600 causes a 500-fold increase in kinase activity and leads to increased cell proliferation [12]. This mutation activates BRAF as a monomer, while in the wild type, the dimer formation is required for the activation [16]. It is structurally shown that BRAF with V600E mutation forms a salt-bridge with residue K507 and stabilizes the active form which it is allosterically adopted only upon dimerization of the wild type (Figure 1B) [16,17]. In addition, V600 is part of a hydrophobic cluster that stabilizes the inactive conformation [13,17]. Dysregulation of the MAPK/ERK signaling pathway is caused by upregulated BRAF activity or impaired kinase activity depending on the BRAF mutation locus [8].
3. Class II BRAF Mutations

Class II mutations, which are RAS-independent kinase activating dimers, contain K601E, L597Q, and G469A. Notably, it has been demonstrated that 13% of BRAF mutations found from 8405 non-small cell lung cancer patients are G469 mutations [23]. Class II mutations exhibit lower ERK phosphorylation activity than BRAF V600E mutation [12]. Class II mutations are mainly located in the activation segment (K601, L597) or P-loop (G464, G469), and the mutations in this location block self-inhibitory mechanism of the kinase activity and maintain higher kinase activity [33]. A recent study has revealed patients with class II mutation in colorectal cancer have worse prognosis than class-III-mutation-carrying patients. Moreover, they confirmed that patients with class I and class II BRAF showed similar poor median overall survival (OS) and disease-free survival [34]. Compared to class I and III mutations, molecular mechanism of the function of class II is less studied.

4. Class III BRAF Mutations

Large-scale tumor sequencing and subsequent functional analysis of individual mutations have revealed that a few mutations possess reduced BRAF kinase activity [8,35]. Class III mutations are located in the P-loop (G466), catalytic loop (N581), or DFG motif (D594, G596). One of these is the mutation at aspartic acid 594 (D594) of the DFG motif, which is a part of the activation loop [8,22,36]. In most protein kinases, the activation segment begins at the DFG motif [37], which plays a crucial role in chelating magnesium, ATP binding, and governs kinase activity [38]. BRAF D594 is located at the active site and its mutation reduces the kinase activity and has been identified in patients suffering from several types of cancer. The D594A mutation differs significantly from the V600E mutation in terms of molecular, pathological, and clinical consequences in metastatic colorectal cancer (mCRC) [18]. In melanoma, myeloma, and colorectal cancer, patients with BRAF mutations at residue D594 have a better prognosis and longer overall survival than those with the V600E mutation [18–20]. In mCRC, D594 mutations were exclusively associated with tumors that were microsatellite stable, unlike V600E. Co-occurrence of mutations at positions 594 and 600 of BRAF is not found, but D594 (D594N) mutation and a concomitant NRAS G13V mutation have been identified in colorectal cancer [18]. Moreover, the kinase-impaired D594 BRAF mutation is associated with the PIK3CA mutation in the mTOR pathway in melanoma [8]. Mutation in the DFG motif results in impaired kinase activity. MEK phosphorylation is completed by different MAPK/ERK protein members. BRAF activates CRAF in a RAS-independent manner. 14-3-3 binding and phosphorylation of the CRAF activation segment are required for signal transduction [39]. Studies of a murine melanoma model have revealed that tumorigenesis is closely related to the inactive BRAF mutation (D594A) and oncogenic RAS. Inhibition of the BRAF D594A mutant in the presence of oncogenic RAS results in heteromerization of BRAF/CRAF and hyperactivation of signal transduction [40].

5. Possible Role of BRAF-ERK-TFs in Cancer Development

Since all the BRAF pathogenic mutations, regardless of their classes, activate ERK phosphorylation, it is hypothesized that transcription factors (TFs) modulated by the ERK signaling pathway are potential downstream targets of BRAF mutations. Notably, it has been suggested that 30% of cancer tissues have constitutively activated RAS-RAF-MEK-ERK [41]. Therefore, it is important to elucidate how downstream effects of ERK phosphorylation are regulated in the context of cancer development in order to inhibit tumor development and progression. However, a limited number of studies are available to link aberrant ERK phosphorylation caused by BRAF mutation and activation of transcription factors in cancer cells. Nonetheless, several studies have identified ERK-target proteins including a number of transcription factors.

One of the best-known transcription factors that are regulated by ERK phosphorylation in cancer cells is cMyc [42]. The persistent activation of cMyc was found when it was phosphorylated at Thr58 and Ser62 [43,44]. This phosphorylation prevents protein degradation. Additionally, the mutation
of cMyc at Thr58, which blocks the degradation of cMyc, has shown resistance to FGFR inhibition in several FGFR-addicted cancer cell lines [45]. These results suggest BRAF mutation-mediated ERK phosphorylation induces cMyc stability and may transfer the tumorigenic signal from BRAF mutations. Another major ERK phosphorylation-driven oncogenic transcription factor is cFos [42]. cFos is a transcription factor that forms a heterodimer with c-Jun and acts as its complex activator protein-1 (AP1). This AP1 dimer protein binds to the AP1-specific DNA sequence of promoter and enhancer regions in target genes. Besides c-Jun, cFos is known to interact with several nuclear transcription factors such as NCOA1 and SMAD3, which are regulated by ERK phosphorylation [42]. Altogether, it is assumed that BRAF mutation-mediated ERK phosphorylation can change the activity of these transcription factor-mediated gene expressions dynamically in cancer cells and exhibit tumor phenotypes.

Apart from these well studied transcription factors, more than 100 transcription factors are determined as targets of ERK phosphorylation by an excellent analysis [42] and, among them, there are several factors that are normally localized in the outside of nucleus and transported to the nucleus after ERK phosphorylation (Figure 3). Interestingly, SMAD 1-4 are found in the list of ERK substrates that are localized in the nucleus and other organelles [42]. SMAD proteins mediate the TGF-β signaling pathway, which is known as a potent regulator of epithelial to mesenchymal transition (EMT). TGF-β1 binds to its receptor II (TβRII) and activates the TGF-β receptor type I (TβRI)-kinase. This leads to phosphorylation of SMAD2 and SMAD3 in the cytoplasm [46]. Thereafter, SMAD2/3 complex is bound to SMAD4 and exerts its transactivation to express target genes. EMT is considered to be a key process in cancer metastasis in multiple cancer types [47,48]. In fact, inhibition of TGF-β signaling pathway using chemical inhibitors blocks EMT in multiple types of cancers [49,50]. These findings suggest that BRAF mutation-induced ERK phosphorylation can enhance phosphorylation of SMAD2/3 and activate EMT capacity of cancer cells.

Figure 3. Transcription factors modulated by the ERK signaling pathway are possible downstream targets of different classes of BRAF mutations. Phosphorylated transcription factors exert their transcriptional activity in the nucleus and stimulate the cancer-inducing target gene expressions.
NRF2, the protein encoded by the NFE2L2 oncogene, is activated by ERK [51] and regulates other genes involved in oxidative stress, including heme-oxygenase and NQO1 (NRF2 major target genes; [52,53]). Several natural compounds, including Sesamin and Curcumin, have been shown to regulate oxidative stress-related genes via the ERK-NRF2 pathway [54,55]. Since the major role of BRAF is to regulate ERK-phosphorylation, NRF2 is likely regulated by BRAF and its mutant V600E form through the ERK signaling pathway in several cancers. In fact, it has been demonstrated that BRAF and RAS mutations induce Nrf2 transcription in mouse primary cells [56]. As aberrant activation of NRF2 is found in multiple cancer types [57], further studies are needed.

During organogenesis, several transcription factors are involved as critical regulators to orchestrate cell fate decision. Interestingly, recent studies have suggested that aberrant function of these factors is highly related to tissue specific cancer development [58]. GATA transcription factors are zinc fingers containing DNA binding proteins and recognize their shared binding consensus sequence W(A/T)GATAR(A/G) [59]. They activate multiple target genes and play key roles in early development, and notably their roles in cancer development has been also reported [58]. In lung development, hepatocyte nuclear factor 3 β (HNF3β) and GATA6 transcription factors are known to be essential factors [60]. GATA6 aberrant expression is important in several cancers including lung cancer [61,62]. Moreover, GATA6 has been reported to regulate the chromatin landscape of lung cancer cells to modulate the proliferation and divergent lineage dependencies during tumor progression. HNF3β is a tumor suppressor in lung cancer, and its overexpression inhibits growth in lung cancer cells [63]. Although the role of ERK-mediated phosphorylation on HNF3β function is still unclear, the enhancement of GATA6 function through ERK phosphorylation in target gene expression is well documented in colon cancer CaCo-2 cells [64]. On the other hand, the combination of HNF4A and HNF3α, β, γ, or HNF1A/HNF3γ/GATA4 with inactivation of p19Arf can generate hepatocyte-like cells [65,66], suggesting that these factors play important roles in liver development. Liver-specific deletion of Gata4 allele (haploinsufficiency) that inhibits GATA4 function leads to the HCC phenotype in mouse [67]. HNF4A, a known hepatic transcription factor, inhibits the ERK pathway through downregulation of phosphorylated ERK and JunD, leading to liver cirrhosis in rats [68]. HNF4A, a tumor suppressor in the liver [69], thus may act as an inhibitor of ERK-phosphorylation-mediated tumor development. Altogether, ERK phosphorylation-mediated regulation of transcription factor action is governed by a complicated regulatory network and further investigation into BRAF mutation-induced ERK phosphorylation in cancer development is required.

6. Aberrant Transcriptional Networks in BRAF Mutations

If BRAF-ERK-TFs pathway plays a central role in cancer development, validation of downstream BRAF target genes is required to generate more specific targets for treatment of BRAF mutation-driven tumorigenesis. In thyroid carcinoma, RNA-Seq analysis has identified that 560 genes are differentially expressed in BRAF V600E-mutated tumors compared to BRAF wild-type tumors [70]. Notably, 51 genes are downregulated and four genes (HLAG, CXCL14, TIMP1, and IL1RAP) are upregulated in immune function pathways. Thus, it is postulated that BRAF acts not only as an activator but also as a repressor. In fact, BRAF V600E has been shown to act as a regulator of the polycomb repressive complex 2 (PRC2) through upregulation of cMyc in NIH3T3 cells [71]. Thirty-three tumors from papillary thyroid cancer were immune histologically analyzed, and it was found that high levels of immunosuppressive-ligand-programmed death ligand 1 (53% vs. 12.5%) and human leukocyte antigen G (41% vs. 12.5%) were expressed in the tumors with BRAF V600E, compared to BRAF wild-type tumors [72]. Moreover, the authors found BRAF V600E tumors show both lower CD8(+) effector to FoxP3(+) regulatory T cell, and CD68(+) pan-macrophage to CD163(+) M2 macrophage, ratios, and suggested that PTC tumors with BRAF V600E displays a broadly immunosuppressive profile and disturbed host tumor immune surveillance [72]. In melanoma, BRAF V600E has been shown to regulate 1027 protein-coding transcripts; 39 annotated IncRNAs; as well as 70 unannotated, potentially novel, intergenic transcripts [73]. Moreover, they identified BRAF-regulated IncRNA1 (BANCR),
and demonstrated that BANCR knockdown reduced melanoma cell migration, and the effect was rescued by the chemokine CXCL11 [73]. Other studies using colorectal cancer (CRC) cell lines and a mouse xenograft model revealed that, in the presence of BRAF V600E, the expression of growth regulation by estrogen in breast cancer protein 1 (GREB1) is highly upregulated compared to WT [74]. BRAF-mutated dysregulation of the MAPK/ERK signaling pathway results in the increased proliferation rate of CRC cells, while high expression of GREB1 may predict poor prognosis for CRC patients, suggesting GREB1 as a possible target for therapy [74]. Aberrant methylation was demonstrated in the HOXD10 promoter in papillary thyroid cancer (PTC) tissues with concomitant BRAF V600E mutation [75]. Since HOXD10 may be considered as a tumor suppressor, the hypermethylation of the promoter decreases its expression, and it may affect tumorigenesis of PTC. Furthermore, AACS, ALDH3B1, ITPR3, MMD, LADI, PVRL3, and RASA1 were proposed as BRAF V600E-dependent genes in thyroid carcinoma [76]. Interestingly, lower gene expression of GADD45B was associated with BRAF V600E, while higher GADD45B expression was connected with shorter disease-free survival in patients after total thyroidectomy and radioiodine therapy in long-term follow-up [77]. GADD45B was recognized as a marker of poor prognosis of PTC. In another study in which PTC samples harboring BRAF V600E and WT were analyzed, the upregulation of CRABP2, ECM1, and KRT17 was recognized, while MTMR3 was downregulated [78]. Since BRAF inhibitors exert non-specific effects, the identification of BRAF-specific target genes is important for the development of a cell-specific inhibitor to block BRAF mutation-mediated cancer progression. Identifying target genes and determining the level of their deregulation caused by an abnormal signaling network is critical for the successful treatment of patients with many types of cancer. The gene expression profiles of patients with BRAF V600E metastatic melanoma who showed varying progression-free survival (PFS) outcomes have been investigated [79]. Interestingly, patients with better PFS represented higher expression of immune-related genes, whereas worse PFS was found in patients with higher expression of cell cycle progression genes. In patients with shorter PFS treated with cobimetinib combined with vemurafenib, the PFS was comparable to patients with longer PFS, unlike vemurafenib-treated alone patients with shorter PFS. Furthermore, the combined therapy had no effect on upregulation of immune regulatory genes in vemurafenib-treated patients with longer PFS. These results emphasize the importance of gene profiling of individuals before applying a specific therapy. Several drugs such as vemurafenib, dabrafenib (BRAF inhibitors), and trametinib (a MEK inhibitor) have been developed to treat patients with BRAF mutations [80]. In most cases, BRAF kinase activity is enhanced by mutations, and BRAF inhibitors are expected to dampen the activity. However, the D594 mutation is known to be kinase-dead, and it enhances tumor progression by stimulating CRAF activity with oncogenic RAS [39]. Therefore, mutation type-dependent therapy should be considered to treat different classes of BRAF mutations. Up to now, a limited number of high-throughput analyses have been performed for BRAF mutations in a few cancer types. To better understand the disrupted transcriptional network caused by BRAF mutations, similar analysis should be performed in different cell types to identify cell-specific BRAF mutation-regulating genes.

7. Conclusions

Many studies have provided new insight into novel personalized anti-cancer therapies that target specific mutations. This highlights the importance of diverse BRAF mutations in various types of cancer. BRAF mutations in the kinase activation segment induce significant changes in the MAPK/ERK signaling pathway. The clinical impact of these mutations is locus-dependent. Within the MAPK/ERK pathway, information from external stimuli to the cell nucleus is not transduced linearly. Therefore, it is crucial to unravel the molecular mechanisms underlying signal transmission changes in the context of a specific mutation. Accordingly, molecular analysis such as RNA sequencing to identify aberrant gene expressions and transcriptional networks in the presence of different BRAF mutations should be performed in order to inform personalized anti-cancer treatment. To this end, these novel therapies should target specific mutations and their downstream effects.
Author Contributions: Conceptualization, H.T., M.Ś., and C.W.; software, H.K.; writing—original draft preparation, M.Ś., H.T., and P.L.; writing—review and editing, P.L., C.W., H.K., and K.D.; supervision, H.T.; funding acquisition, M.Ś. All authors have read and agreed to the published version of the manuscript.

Funding: This study was financially supported by National Science Centre, Poland (grant no. 2017/25/N/ZN5/01885) to M.Ś. The protein structure and computational analysis were supported by the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from Japan Agency for Medical Research and Development (AMED) under Grant Number JP19am0101060j0003 (support number 1538) to H.K. and RIKEN Pioneering research project, Dynamic Structural Biology, to H.K.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kondoh, K.; Nishida, E. Regulation of MAP Kinases by MAP Kinase Phosphatases. *Biochim. Biophys. Acta* 2007, 1773, 1227–1237. [CrossRef] [PubMed]

2. Robinson, M.J.; Cobb, M.H. Mitogen-Activated Protein Kinase Pathways. *Curr. Opin. Cell Biol.* 1997, 9, 180–186. [CrossRef]

3. Whitmarsh, A.J. Regulation of Gene Transcription by Mitogen-Activated Protein Kinase Signaling Pathways. *Biochim. Biophys. Acta* 2007, 1773, 1285–1298. [CrossRef] [PubMed]

4. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrion, D.M.; Milella, M.; Tafuri, A.; et al. Roles of the Raf/MEK/ERK Pathway in Cell Growth, Malignant Transformation and Drug Resistance. *Biochim. Biophys. Acta* 2007, 1773, 1263–1284. [CrossRef]

5. Murphy, L.O.; Blenis, J. MAPK Signal Specificity: The Right Place at the Right Time. *Trends Biochem. Sci.* 2006, 31, 268–275. [CrossRef]

6. Zhang, W.; Liu, H.T. MAPK Signal Pathways in the Regulation of Cell Proliferation in Mammalian Cells. *Cell Res.* 2002, 12, 9–18. [CrossRef]

7. Garnett, M.J.; Marais, R. Guilty as Charged: B-RAF is a Human Oncogene. *Cancer Cell* 2004, 6, 313–319. [CrossRef]

8. Zheng, G.; Tseng, L.H.; Chen, G.; Haley, L.; Illei, P.; Gocke, C.D.; Eshleman, J.R.; Lin, M.T. Clinical Detection and Categorization of Uncommon and Concomitant Mutations Involving BRAF. *BMC Cancer* 2015, 15, 779. [CrossRef]

9. Wenglowsky, S.; Ren, L.; Ahrendt, K.A.; Laird, E.R.; Aliagas, I.; Alickie, B.; Buckmelter, A.J.; Choo, E.F.; Dinkel, V.; Feng, B.; et al. Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. *ACS Med. Chem. Lett.* 2011, 2, 342–347. [CrossRef]

10. Rahman, M.A.; Salajegheh, A.; Smith, R.A.; Lam, A.K. B-Raf Mutation: A Key Player in Molecular Biology of Cancer. *Exp. Mol. Pathol.* 2013, 95, 336–342. [CrossRef]

11. Haling, J.R.; Sudhamsu, J.; Yen, I.; Sideris, S.; Sandooval, W.; Phung, W.; Bravo, B.J.; Giannetti, A.M.; Peck, A.; Masselot, A.; et al. Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling. *Cancer. Cell* 2014, 26, 402–413. [CrossRef]
17. Park, E.; Rawson, S.; Li, K.; Kim, B.W.; Picarro, S.B.; Pino, G.G.; Sharif, H.; Marto, J.A.; Jeon, H.; Eck, M.J. Architecture of Autoinhibited and Active BRAF-MEK1-14-3-3 Complexes. *Nature* **2019**, *575*, 545–550. [CrossRef]

18. Cremolini, C.; Di Bartolomeo, M.; Amatu, A.; Antoniotti, C.; Moretto, R.; Berenato, R.; Perrone, F.; Tamborini, E.; Aprile, G.; Lonardi, S.; et al. BRAF Codons 594 and 596 Mutations Identify a New Molecular Subtype of Metastatic Colorectal Cancer at Favorable Prognosis. *Ann. Oncol.* **2015**, *26*, 2092–2097. [CrossRef]

19. Wu, X.; Yan, J.; Dai, J.; Ma, M.; Tang, H.; Yu, J.; Xu, T.; Yu, H.; Si, L.; Chi, Z.; et al. Mutations in BRAF Codons 594 and 596 Predict Good Prognosis in Melanoma. *Oncol. Lett.* **2017**, *14*, 3601–3605. [CrossRef]

20. Boyle, E.M.; Ashby, C.; Tytarenko, R.; Deshpande, S.; Wang, Y.; Sawyer, J.; Tian, E.; Johnson, S.; Rutherford, M.W.; Wardell, C.P.; et al. BRAF and DUS3 Mutations Associate with Adverse Outcome in a Long-Term Follow-Up of Patients with Multiple Myeloma. *Clin. Cancer Res.* **2020**, *26*, 2422–2432. [CrossRef]

21. Walker, B.A.; Mavrommatis, K.; Wardell, C.P.; Ashby, T.C.; Bauer, M.; Davies, F.E.; Rosenthal, A.; Wang, H.; Qu, P.; Hoering, A.; et al. Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma. *Blood* **2018**, *132*, 587–597. [CrossRef] [PubMed]

22. Yao, Z.; Yaeger, R.; Rodrik-Outmezguine, V.S.; Tao, A.; Torres, N.M.; Chang, M.T.; Drosten, M.; Zhao, H.; Cecchi, F.; Hembrough, T.; et al. Tumours with Class 3 BRAF Mutants are Sensitive to the Inhibition of Activated RAS. *Nature* **2017**, *548*, 234–238. [CrossRef] [PubMed]

23. Lin, Q.; Zhang, H.; Ding, H.; Qian, J.; Lizaso, A.; Lin, J.; Han-Zhang, H.; Xiang, J.; Li, Y.; Zhu, H. The Association between BRAF Mutation Class and Clinical Features in BRAF-Mutant Chinese Non-Small Cell Lung Cancer Patients. *J. Transl. Med.* **2019**, *17*, 298. [CrossRef] [PubMed]

24. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Wootterson, J.; Goebbels, S.; Mungall, A.; among others. Discovering the Full Extent of the RASopathies. *Nat. Rev. Genet.* **2012**, *13*, 671–682. [CrossRef] [PubMed]

25. Ikenoue, T.; Hikiba, Y.; Kanai, F.; Tanaka, Y.; Imamura, J.; Imamura, T.; Ohta, M.; Ijichi, H.; Tateishi, K.; Houben, R.; Becker, J.C.; Kappel, A.; Terheyden, P.; Brocker, E.B.; Goetz, R.; Rapp, U.R. Constitutive Activation of the Ras-Raf Signaling Pathway in Metastatic Melanoma is Associated with Poor Prognosis. *Clin. Cancer Res.* **2011**, *17*, 3294–3300. [CrossRef] [PubMed]

26. Naoki, K.; Chen, T.H.; Richards, W.G.; Sugarbaker, D.J.; Meyerson, M. Missense Mutations of the BRAF Gene in Human Lung Adenocarcinomas. *Ann. Surg. Oncol.* **2013**, *20*, 365–374. [CrossRef] [PubMed]

27. Lavoie, H.; Therrien, M. Regulation of RAF Protein Kinases in ERK Signalling. *Nat. Rev. Mol. Cell Biol.* **2002**, *3*, 179–189. [CrossRef] [PubMed]

28. Andruslis, M.; Lehnars, N.; Capper, D.; Penzel, R.; Heining, C.; Huellein, J.; Zenz, T.; von Deimling, A.; Schirripa, M.; Biason, P.; Lonardi, S.; Pella, N.; Pino, M.S.; Urbano, F.; Antoniotti, C.; Cremolini, C.; Corallo, S.; Pietrantonio, F.; et al. Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. *Clin. Cancer Res.* **2019**, *25*, 3954–3961. [CrossRef] [PubMed]

29. Moretti, S.; De Falco, V.; Tamburrino, A.; Barbì, F.; Taverno, M.; Avenia, N.; Santeusanio, F.; Santoro, M.; Macchiarulo, A.; Puxeddu, E. Insights into the Molecular Function of the Inactivating Mutations of B-Raf Involving the DFG Motif. *Biochim. Biophys. Acta* **2009**, *1793*, 1634–1645. [CrossRef] [PubMed]
36. Hari, S.B.; Merritt, E.A.; Maly, D.I. Sequence Determinants of a Specific Inactive Protein Kinase Conformation. Chem. Biol. 2013, 20, 806–815. [CrossRef]
37. Vijayan, R.S.; He, P.; Modi, V.; Duong-Ly, K.C.; Ma, H.; Peterson, J.R.; Dunbrack, R.L., Jr.; Levy, R.M. Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. J. Med. Chem. 2015, 58, 466–479. [CrossRef]
38. Johnson, L.N.; Lowe, E.D.; Noble, M.E.; Owen, D.J. The Eleventh Datta Lecture. the Structural Basis for Substrate Recognition and Control by Protein Kinases. FEBS Lett. 1998, 430, 1–11. [CrossRef]
39. Garnett, M.J.; Rana, S.; Paterson, H.; Barford, D.; Marais, R. Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization. Mol. Cell 2005, 20, 963–969. [CrossRef]
40. Heidorn, S.J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010, 140, 209–221. [CrossRef]
41. Scholl, F.A.; Dumesic, P.A.; Khavari, P.A. Effects of Active MEK1 Expression in Vivo. Cancer Lett. 2005, 230, 1–5. [CrossRef]
42. Maik-Rachline, G.; Hacohen-Lev-Ran, A.; Seger, R. Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer. Int. J. Mol. Sci. 2019, 20, 1194. [CrossRef]
43. Pulverer, B.J.; Fisher, C.; Vosden, K.; Littlewood, T.; Evan, G.; Woodgett, J.R. Site-Specific Modulation of c-Myc Cotransformation by Residues Phosphorylated in Vivo. Oncogene 1994, 9, 59–70.
44. Sears, R.; Nuckolls, F.; Haura, E.; Taya, Y.; Tamai, K.; Nevins, J.R. Multiple Ras-Dependent Phosphorylation Pathways Regulate Myc Protein Stability. Genes Dev. 2000, 14, 2501–2514. [CrossRef]
45. Liu, H.; Ai, J.; Shen, A.; Chen, Y.; Wang, X.; Peng, X.; Chen, H.; Shen, Y.; Huang, M.; Ding, J.; et al. C-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Clin. Cancer Res. 2017, 23, 974–984. [CrossRef]
46. Lan, H.Y. Diverse Roles of TGF-beta/Smads in Renal Fibrosis and Inflammation. Int. J. Biol. Sci. 2011, 7, 1056–1067. [CrossRef]
47. Brabletz, T.; Kalluri, R.; Nieto, M.A.; Weinberg, R.A. EMT in Cancer. Nat. Rev. Cancer 2018, 18, 128–134. [CrossRef]
48. Dongre, A.; Weinberg, R.A. New Insights into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer. Nat. Rev. Mol. Cell Biol. 2019, 20, 69–84. [CrossRef]
49. Guo, Y.; Cui, W.; Pei, Y.; Xu, D. Platelets Promote Invasion and Induce Epithelial to Mesenchymal Transition in Ovarian Cancer Cells by TGF-Beta Signaling Pathway. Gynecol. Oncol. 2019, 153, 639–650. [CrossRef]
50. Wang, X.L.; Huang, C. Difference of TGF-beta/Smads Signaling Pathway in Epithelial-Mesenchymal Transition of Normal Colon Epithelial Cells Induced by Tumor-Associated Fibroblasts and Colon Cancer Cells. Mol. Biol. Rep. 2019, 46, 2749–2759. [CrossRef]
51. Zipper, L.M.; Mulcahy, R.T. Erk Activation is Required for Nrf2 Nuclear Localization during Pyrrolidine Dithiocarbamate Induction of Glutamate Cysteine Ligase Modulatory Gene Expression in HepG2 Cells. Toxicol. Sci. 2003, 73, 124–134. [CrossRef]
52. Cho, S.J.; Ryu, J.H.; Surh, Y.J. Ajoene, a Major Organosulfide found in Crushed Garlic, Induces NAD(P)H:Quinone Oxidoreductase Expression through Nuclear Factor E2-Related Factor-2 Activation in Human Breast Epithelial Cells. J. Cancer Prev. 2019, 24, 112–122. [CrossRef]
53. Jang, H.J.; Hong, E.M.; Kim, M.; Kim, J.H.; Jang, J.; Park, S.W.; Byun, H.W.; Koh, D.H.; Choi, M.H.; Kae, S.H.; et al. Simvastatin Induces Heme Oxygenase-1 Via NF-E2-Related Factor 2 (Nrf2) Activation through ERK and PI3K/Akt Pathway in Colon Cancer. Oncotarget 2016, 7, 46219–46229. [CrossRef]
54. Bai, X.; Gou, X.; Cai, P.; Xu, C.; Cao, L.; Zhao, Z.; Huang, M.; Jin, J. Sessamin Enhances Nrf2-Mediated Protective Defense Against Oxidative Stress and Inflammation in Colitis Via AKT and ERK Activation. Oxidative Med. Cell. Longev. 2019, 2019, 2432416. [CrossRef]
55. Bucolo, C.; Drago, F.; Maisto, R.; Romano, G.L.; D’Agata, V.; Maugeri, G.; Giunta, S. Curcumin Prevents High Glucose Damage in Retinal Pigment Epithelial Cells through ERK1/2-Mediated Activation of the Nrf2/HO-1 Pathway. J. Cell. Physiol. 2019, 234, 17295–17304. [CrossRef]
56. DeNicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; et al. Oncogene-Induced Nrf2 Transcription Promotes ROS Detoxification and Tumorigenesis. Nature 2011, 475, 106–109. [CrossRef]
57. Zimta, A.A.; Cenariu, D.; Irimie, A.; Magdo, L.; Nabavi, S.M.; Atanasov, A.G.; Berindan-Neagoe, I. The Role of Nrf2 Activity in Cancer Development and Progression. *Cancers* **2019**, *11*, 1755. [CrossRef]

58. Huilgol, D.; Venkataramani, P.; Nandi, S.; Bhattacharjee, S. Transcription Factors that Govern Development and Disease: An Achilles Heel in Cancer. *Genes* **2019**, *10*, 794. [CrossRef]

59. Tremblay, M.; Sanchez-Ferras, O.; Bouchard, M. GATA Transcription Factors in Development and Disease. *Development* **2018**, *145*. [CrossRef]

60. Bonner, A.E.; Lemon, W.J.; You, M. Gene Expression Signatures Identify Novel Regulatory Pathways during Murine Lung Development: Implications for Lung Tumorigenesis. *J. Med. Genet.* **2003**, *40*, 408–417. [CrossRef]

61. Ma, R.; Li, X.; Liu, H.; Jiang, R.; Yang, M.; Zhang, M.; Wang, Y.; Zhao, Y.; Li, H. GATA6-Upregulating Autophagy Promotes TKI Resistance in Nonsmall Cell Lung Cancer. *Cancer Biol. Ther.* **2019**, *20*, 1206–1212. [CrossRef]

62. Sun, Z.; Yan, B. Multiple Roles and Regulatory Mechanisms of the Transcription Factor GATA6 in Human Cancers. *Clin. Genet.* **2020**, *97*, 64–72. [CrossRef]

63. Halmos, B.; Basseres, D.S.; Monti, S.; D’Alo, F.; Dayaram, T.; Ferenci, K.; Wouters, B.J.; Huetttner, C.S.; Golub, T.R.; Tenen, D.G. A Transcriptional Profiling Study of CCAAT/enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3 Beta as a Novel Tumor Suppressor in Lung Cancer. *Cancer Res.* **2004**, *64*, 4137–4147. [CrossRef]

64. Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W.H.; Hirose, K.; Kamata, T. Oncogenic Ras Upregulates NADPH Oxidase 1 Gene Expression through MEK-ERK-Dependent Phosphorylation of GATA-6. *Oncogene* **2008**, *27*, 4921–4932. [CrossRef]

65. Sekiya, S.; Suzuki, A. Direct Conversion of Mouse Fibroblasts to Hepatocyte-Like Cells by Defined Factors. *Nature* **2011**, *475*, 390–393. [CrossRef]

66. Huang, P.; He, Z.; Ji, S.; Sun, H.; Xiang, D.; Liu, C.; Hu, Y.; Wang, X.; Hui, L. Induction of Functional Hepatocyte-Like Cells from Mouse Fibroblasts by Defined Factors. *Nature* **2011**, *475*, 386–389. [CrossRef]

67. Enane, F.O.; Shuen, W.H.; Gu, X.; Quteba, E.; Przychodzen, B.; Makishima, H.; Bodo, J.; Ng, J.; Chee, C.L.; Ba, R.; et al. GATA4 Loss of Function in Liver Cancer Impedes Precursor to Hepatocyte Transition. *J. Clin. Investig.* **2017**, *127*, 3527–3542. [CrossRef]

68. Fan, T.T.; Hu, P.F.; Wang, J.; Wei, J.; Zhang, Q.; Ning, B.F.; Yin, C.; Zhang, X.; Xie, W.F.; Chen, Y.X.; et al. Regression Effect of Hepatocyte Nuclear Factor 4alpha on Liver Cirrhosis in Rats. *J. Dig. Dis.* **2013**, *14*, 318–327. [CrossRef]

69. Ning, B.F.; Ding, J.; Yin, C.; Zhong, W.; Wu, K.; Zeng, X.; Yang, W.; Chen, Y.X.; Zhang, J.P.; Zhang, X.; et al. Hepatocyte Nuclear Factor 4 Alpha Suppresses the Development of Hepatocellular Carcinoma. *Cancer Res.* **2010**, *70*, 7640–7651. [CrossRef]

70. Smallridge, R.C.; Chindris, A.M.; Asmann, Y.W.; Casler, J.D.; Serie, D.J.; Reddi, H.V.; Cradic, K.W.; Rivera, M.; Grebe, S.K.; Necela, B.M.; et al. RNA Sequencing Identifies Multiple Fusion Transcripts, Differentially Expressed Genes, and Reduced Expression of Immune Function Genes in BRAF(V600E) Mutant Vs BRAF Wild-Type Papillary Thyroid Carcinoma. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E338–E347. [CrossRef]

71. Qu, Y.; Yang, Q.; Liu, J.; Shi, B.; Ji, M.; Li, G.; Hou, P. C-Myc is Required for BRAF(V600E)-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis. *Theranostics* **2017**, *7*, 2092–2107. [CrossRef] [PubMed]

72. Angell, T.E.; Lechner, M.G.; Jang, J.K.; Correa, A.J.; LoPresti, J.S.; Epstein, A.L. BRAF V600E in Papillary Thyroid Carcinoma is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. *Thyroid* **2014**, *24*, 1385–1393. [CrossRef] [PubMed]

73. Flockhart, R.J.; Webster, D.E.; Qu, K.; Mascarenhas, N.; Kovalski, J.; Kretz, M.; Khavari, P.A. BRAFV600E Remodels the Melanocyte Transcriptome and Induces BANCIR to Regulate Melanoma Cell Migration. *Genome Res.* **2012**, *22*, 1006–1014. [CrossRef] [PubMed]

74. Kochi, M.; Hinoi, T.; Niitsu, H.; Miguchi, M.; Saijo, Y.; Sada, H.; Sentani, K.; Sakamoto, N.; Oue, N.; Tashiro, H.; et al. Oncogenic Mutation in RAS-RAF Axis Leads to Increased Expression of GREB1, Resulting in Tumor Proliferation in Colorectal Cancer. *Cancer Sci.* **2020**, *111*, 3540–3549. [CrossRef] [PubMed]

75. Cao, Y.M.; Gu, J.; Zhang, Y.S.; Wei, W.J.; Qu, N.; Wen, D.; Liao, T.; Shi, R.L.; Zhang, L.; Ji, Q.H.; et al. Aberrant Hypermethylation of the HOXD10 Gene in Papillary Thyroid Cancer with BRAFV600E Mutation. *Oncol. Rep.* **2018**, *39*, 338–348. [CrossRef]
76. Rusinek, D.; Swierniak, M.; Chmielik, E.; Kowal, M.; Kowalska, M.; Cyplinska, R.; Czarniecka, A.; Piglowski, W.; Korfanty, J.; Chekan, M.; et al. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. *PLoS ONE* **2015**, *10*, e0143688. [CrossRef]

77. Barros-Filho, M.C.; de Mello, J.B.H.; Marchi, F.A.; Pinto, C.A.L.; da Silva, I.C.; Damasceno, P.K.F.; Soares, M.B.P.; Kowalski, L.P.; Rogatto, S.R. GADD45B Transcript is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated with Total Thyroidectomy and Radioiodine Therapy. *Front. Endocrinol.* **2020**, *11*, 269. [CrossRef]

78. Rusinek, D.; Pfeifer, A.; Cieslicka, M.; Kowalska, M.; Pawlaczek, A.; Krajewska, J.; Szpak-Ulczok, S.; Tyszkiewicz, T.; Halczok, M.; Czarniecka, A.; et al. TERT Promoter Mutations and their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. *Cancers* **2020**, *12*, 1597. [CrossRef]

79. Wongchenko, M.J.; McArthur, G.A.; Dreno, B.; Larkin, J.; Ascierto, P.A.; Sosman, J.; Andries, L.; Kockx, M.; Hurst, S.D.; Caro, I.; et al. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib that may be Overcome by Cobimetinib Plus Vemurafenib. *Clin. Cancer Res.* **2017**, *23*, 5238–5245. [CrossRef]

80. Patel, H.; Yacoub, N.; Mishra, R.; White, A.; Long, Y.; Alanazi, S.; Garrett, J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. *Cancers* **2020**, *12*, 482. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).